[1]乾贝贝 闫彩凤.SGLTs抑制剂对骨代谢的影响及其机制[J].国际内分泌代谢杂志,2019,39(06):422-425,428.[doi:10.3760/cma.j.issn.1673-4157.2019.06.015]
　Qian Beibei,Yan Caifeng.Impact of SGLTs inhibitors on bone metabolism and its mechanism[J].International Journal of Endocrinology and Metabolism,2019,39(06):422-425,428.[doi:10.3760/cma.j.issn.1673-4157.2019.06.015]
点击复制

SGLTs抑制剂对骨代谢的影响及其机制()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年06期
页码:
422-425,428
栏目:
综述
出版日期:
2019-11-20

文章信息/Info

Title:
Impact of SGLTs inhibitors on bone metabolism and its mechanism
作者:
乾贝贝1 闫彩凤2
1大连医科大学研究生院 116044; 2江苏省苏北人民医院内分泌科,扬州 225001
Author(s):
Qian Beibei1;  Yan Caifeng2
1Graduate School, Dalian Medical University, Dalian 116044, China; 2Department of Endocrinology, Subei People’s Hospital of Jiangsu Province, Yangzhou 225001, China
关键词:
钠-葡萄糖协同转运蛋白;  钠-葡萄糖协同转运蛋白2抑制剂;  2型糖尿病;  骨代谢;  骨折
Keywords:
Sodium-glucose transporter;  Sodium-glucose transporter 2 inhibitors;  Type 2 diabetes mellitus;  Bone metabolism;  Fracture
DOI:
10.3760/cma.j.issn.1673-4157.2019.06.015
摘要:
新型降糖药物钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂能够改变矿物质水平、影响骨转换标志物、降低骨密度、破坏骨微结构、加速骨转换以及可能增加跌倒风险,提示其可能对骨代谢及糖尿病患者骨折结局产生影响,探讨其潜在机制并评估接受该药治疗的骨折风险对临床实践中的药物选择有重要的指导意义。
Abstract:
Sodium-glucose transporter 2(SGLT2)inhibitors, the novel anti-diabetic drugs, can change the levels of minerals, affect bone turnover markers, reduce bone mineral density, disrupt bone microarchitecture, accelerate bone turnover and may increase the susceptibility to falls. It suggests that it may have an impact on bone metabolism and fracture outcomes in patients with diabetes mellitus. It is of great significance to explore its potential mechanisms and evaluate the risk of fractures caused by the drug for selection of drug in clinical practice.

参考文献/References:

[1] Moayeri A,Mohamadpour M,Mousavi SF,et al.Fracture risk in patients with type 2 diabetes mellitus and possible risk factors: a systematic review and meta-analysis[J].Ther Clin Risk Manag,2017,13:455-468.DOI:10.2147/TCRM.S131945.
[2] Heerspink HJ,Perkins BA,Fitchett DH,et al.Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications[J].Circulation,2016,134(10):752-772.DOI:10.1161/CIRCULATIONAHA.116.021887.
[3] Perkovic V,Jardine MJ,Neal B,et al.Canagliflozin and renal outcomes in type 2 diabetes and nephropathy[J].N Engl J Med,2019,380(24):2295-2306.DOI:10.1056/NEJMoa1811744.
[4] Markham A,Keam SJ.Sotagliflozin:first global approval[J].Drugs,2019,79(9):1023-1029.DOI:10.1007/s40265-019-01146-5.
[5] Musso G,Gambino R,Cassader M,et al.Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials[J].BMJ,2019,365:11328.DOI:10.1136/bmj.l1328.
[6] Cefalo CMA,Cinti F,Moffa S,et al.Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives[J].Cardiovasc Diabetol,2019,18(1):20.DOI:10.1186/s12933-019-0828-y.
[7] Nauck MA.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes[J].Drug Des Devel Ther,2014,8:1335-1380.DOI:10.2147/DDDT.S50773.
[8] Blau JE,Bauman V,Conway EM,et al.Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study[J].JCI Insight,2018,3(8):pii:99123.DOI:10.1172/jci.insight.99123.
[9] Alba M,Xie J,Fung A,et al.The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus[J].Curr Med Res Opin,2016,32(8):1375-1385.DOI:10.1080/03007995.2016.1174841.
[10] Thrailkill KM,Nyman JS,Bunn RC,et al.The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes[J].Bone,2017,94:141-151.DOI:10.1016/j.bone.2016.10.026.
[11] de Jong MA,Petrykiv SI,Laverman GD,et al.Effects of dapagliflozin on circulating markers of phosphate homeostasis[J].Clin J Am Soc Nephrol,2019,14(1):66-73.DOI:10.2215/CJN.04530418.
[12] Samadfam R,Doyle N,Kissner T,et al. Anti-diabetes drug class of SGLT1 inhibitors increases bone mass in young and adult female Sprague-Dawley rats by decreasing bone turnover[J]. Can J Diabetes,2013,37: S6.DOI:org/10.1016/j.jcjd.2013.08.013.
[13] Barsony J,Sugimura Y,Verbalis JG.Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss[J].J Biol Chem,2011,286(12):10864-10875.DOI:10.1074/jbc.M110.155002.
[14] Hoorn EJ,Liamis G,Zietse R,et al.Hyponatremia and bone: an emerging relationship[J].Nat Rev Endocrinol,2011,8(1):33-39.DOI:10.1038/nrendo.2011.173.
[15] Kizilgul M,Ozcelik O,Apaydin M,et al.Letter to the editor: possible mechanisms of hyponatremia-induced osteoporosis[J].J Clin Endocrinol Metab,2015,100(10):L89-L90.DOI:10.1210/jc.2015-2631.
[16] Basu S,Micha?lsson K,Olofsson H,et al.Association between oxidative stress and bone mineral density[J].Biochem Biophys Res Commun,2001,288(1):275-279.DOI:10.1006/bbrc.2001.5747.
[17] Glendenning P.Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards: osteoporos int 2011; 22:391-420[J].Clin Biochem Rev,2011,32(1):45-47.
[18] Bilezikian JP,Watts NB,Usiskin K,et al.Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin[J].J Clin Endocrinol Metab,2016,101(1):44-51.DOI:10.1210/jc.2015-1860.
[19] Thrailkill KM,Bunn RC,Nyman JS,et al.Corrigendum to "SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice" [Bone 82(2016)101-107][J].Bone,2017,105:316.DOI:10.1016/j.bone.2016.11.021.
[20] Ljunggren ?,Bolinder J,Johansson L,et al.Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin[J].Diabetes Obes Metab,2012,14(11):990-999.DOI:10.1111/j.1463-1326.2012.01630.x.
[21] Ghezzi C,Yu AS,Hirayama BA,et al.Dapagliflozin binds specifically to sodium-glucose cotransporter 2 in the proximal renal tubule[J].J Am Soc Nephrol,2017,28(3):802-810.DOI:10.1681/ASN.2016050510.
[22] Rosenstock J,Frias J,Páll D,et al.Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy(VERTIS MET)[J].Diabetes Obes Metab,2018,20(3):520-529.DOI:10.1111/dom.13103.
[23] Thrailkill KM,Clay Bunn R,Nyman JS,et al.SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice[J].Bone,2016,82:101-107.DOI:10.1016/j.bone.2015.07.025.
[24] Beitelshees AL,Leslie BR,Taylor SI.Sodium-glucose cotransporter 2 inhibitors: a case study in translational research[J].Diabetes,2019,68(6):1109-1120.DOI:10.2337/dbi18-0006.
[25] Williams GA,Wang Y,Callon KE,et al.In vitro and in vivo effects of adiponectin on bone[J].Endocrinology,2009,150(8):3603-3610.DOI:10.1210/en.2008-1639.
[26] Tamura T,Yoneda M,Yamane K,et al.Serum leptin and adiponectin are positively associated with bone mineral density at the distal radius in patients with type 2 diabetes mellitus[J].Metabolism,2007,56(5):623-628.DOI:10.1016/j.metabol.2006.12.008.
[27] Campos RMDS,Masquio DCL,Corgosinho FC,et al.Relationship between adiponectin and leptin on osteocalcin in obese adolescents during weight loss therapy[J]. Arch Endocrinol Metab,2018,62(3):275-284.DOI:10.20945/2359-3997000000039.
[28] Napolitano A,Miller S,Murgatroyd PR,et al.Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects[J].J Clin Transl Endocrinol,2013,1(1):e3-e8.DOI:10.1016/j.jcte.2013.12.001.
[29] Jansson JO,Palsdottir V,H?gg DA,et al.Body weight homeostat that regulates fat mass independently of leptin in rats and mice[J].Proc Natl Acad Sci U S A,2018,115(2):427-432.DOI:10.1073/pnas.1715687114.
[30] Neal B,Perkovic V,Mahaffey KW,et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377(7):644-657.DOI:10.1056/NEJMoa1611925.
[31] Watts NB,Bilezikian JP,Usiskin K,et al.Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2016,101(1):157-166.DOI:10.1210/jc.2015-3167.
[32] Fralick M,Kim SC,Schneeweiss S,et al.Fracture risk after initiation of use of canagliflozin: a cohort study[J].Ann Intern Med,2019,170(3):155-163.DOI:10.7326/M18-0567.
[33] Wiviott SD,Raz I,Sabatine MS.Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply[J].N Engl J Med,2019,380(19):1881-1882.DOI:10.1056/NEJMc1902837.
[34] Toulis KA,Bilezikian JP,Thomas GN,et al.Initiation of dapagliflozin and treatment-emergent fractures[J].Diabetes Obes Metab,2018,20(4):1070-1074.DOI:10.1111/dom.13176.
[35] Zinman B,Wanner C,Lachin JM,et al.Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J].N Engl J Med,2015,373(22):2117-2128.DOI:10.1056/NEJMoa1504720.
[36] Schmedt N,Andersohn F,Walker J,et al. Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case-control study[J].Diabetes Obes Metab,2019,21(1):52-60.DOI:10.1111/dom.13480.
[37] Li X,Li T,Cheng Y,et al.Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis[J].Diabetes Metab Res Rev,2019,15:e3170.DOI:10.1002/dmrr.3170.
[38] Azharuddin M,Adil M,Ghosh P,et al.Sodium-glucose cotransporter 2 inhibitors and fracture risk in patients with type 2 diabetes mellitus: a systematic literature review and Bayesian network meta-analysis of randomized controlled trials[J].Diabetes Res Clin Pract,2018,146:180-190.DOI:10.1016/j.diabres.2018.10.019.
[39] Ruanpeng D,Ungprasert P,Sangtian J,et al.Sodium-glucose cotransporter 2(SGLT2)inhibitors and fracture risk in patients with type 2 diabetes mellitus:a meta-analysis[J].Diabetes Metab Res Rev,2017,33(6).DOI:10.1002/dmrr.2903.
[40] Tang HL,Li DD,Zhang JJ,et al.Lack of evidence for a harmful effect of sodium-glucose co-transporter 2(SGLT2)inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials[J].Diabetes Obes Metab,2016,18(12):1199-1206.DOI:10.1111/dom.12742.
[41] Cheng L,Li YY,Hu W,et al.Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials[J].Diabetes Metab,2019,45(5):436-445.DOI:10.1016/j.diabet.2019.01.010.

相似文献/References:

[1]李静 李楠 杨永歆.2型糖尿病患者胰岛素治疗加用达格列净的 疗效及安全性[J].国际内分泌代谢杂志,2018,38(05):289.[doi:10.3760/cma.j.issn.1673-4157.2018.05.001]
　Li Jing*,Li Nan,Yang Yongxin.The efficacy and safety of dapagliflozin in patients with type 2 diabetes receiving insulin therapy[J].International Journal of Endocrinology and Metabolism,2018,38(06):289.[doi:10.3760/cma.j.issn.1673-4157.2018.05.001]
[2]张启伦,叶山东.SGLT2抑制剂肾脏外糖代谢调控机制的研究进展[J].国际内分泌代谢杂志,2021,41(04):360.[doi:10.3760/cma.j.cn121383-20200715-07040]
　Zhang Qilun,Ye Shandong..Research progress of the extrarenal mechanism of SGLT2 inhibitors in the regulation of blood glucose[J].International Journal of Endocrinology and Metabolism,2021,41(06):360.[doi:10.3760/cma.j.cn121383-20200715-07040]

备注/Memo

备注/Memo:
通信作者:闫彩凤, Email:yancaifeng@126.com
Corresponding author: Yan Caifeng, Email: yancaifeng@ 126.com
基金项目:扬州市社会发展基金(YZ2016061)
Fund program:Social Development Foundation of Yangzhou City of China(YZ2016061)
更新日期/Last Update: 2019-11-20